Tamiflu (Oseltamivir) Adult Dosing for Influenza B
The standard adult dose of oseltamivir for treating influenza B is 75 mg orally twice daily for 5 days, with dose reduction to 75 mg once daily (or 30 mg once daily) required when creatinine clearance falls below 30 mL/min. 1, 2
Standard Treatment Regimen
- Adults and adolescents ≥13 years: 75 mg orally twice daily for 5 days 3, 1, 2
- Treatment should be initiated within 48 hours of symptom onset for maximal benefit, though earlier initiation (within 12–24 hours) yields even greater reduction in illness duration 1, 4
- The full 5-day course must be completed even if symptoms improve earlier, to ensure adequate viral suppression and minimize resistance risk 1, 5
Post-Exposure Prophylaxis
- Standard prophylaxis: 75 mg orally once daily for 10 days, initiated within 48 hours of exposure to an infected individual 1, 5, 2
- Community outbreak prophylaxis: 75 mg once daily for up to 6 weeks during periods of local influenza activity 2, 6
Renal Impairment Dose Adjustments
Treatment (5-day course)
| Creatinine Clearance | Adjusted Dose |
|---|---|
| >30–60 mL/min | 30 mg twice daily |
| 10–30 mL/min | 75 mg once daily or 30 mg once daily |
| ESRD on hemodialysis | 30 mg immediately, then 30 mg after each dialysis session (max 5 days) |
| ESRD on CAPD | Single 30 mg dose immediately |
| ESRD not on dialysis | Not recommended |
Prophylaxis
| Creatinine Clearance | Adjusted Dose |
|---|---|
| >30–60 mL/min | 30 mg once daily |
| 10–30 mL/min | 30 mg every other day OR 75 mg every other day (5 total doses over 10 days) |
| ESRD on hemodialysis | 30 mg immediately, then 30 mg after alternate dialysis cycles |
| ESRD on CAPD | 30 mg immediately, then 30 mg once weekly |
Special Considerations for Influenza B
- Higher-dose consideration: A prospective study demonstrated that influenza B patients treated with 150 mg twice daily showed faster viral RNA decline and clearance (80% vs 57.1% by day 5) compared to standard 75 mg dosing, though this higher dose is not FDA-approved 7
- Standard dosing remains appropriate: Despite the above finding, the FDA-approved and guideline-recommended dose remains 75 mg twice daily for all influenza types, including influenza B 1, 2
Administration Guidance
- Take with food: Administration with meals markedly reduces gastrointestinal side effects (nausea occurs in ~10% of patients, vomiting in ~9%) without affecting antiviral efficacy 1, 8, 4
- Available formulations: 30 mg, 45 mg, and 75 mg capsules; oral suspension at 6 mg/mL concentration 1, 9
High-Risk Patients Requiring Treatment Beyond 48 Hours
- Hospitalized patients with severe or progressive influenza should receive oseltamivir regardless of time elapsed since symptom onset 3, 5
- Immunocompromised patients or those unable to mount adequate febrile response may benefit from treatment initiated after 48 hours 3, 5
- Adults ≥65 years, pregnant women, and individuals with chronic cardiac or respiratory disease warrant treatment even when presenting late 1, 5
Critical Pitfalls to Avoid
- Do not confuse treatment and prophylaxis dosing: Treatment is twice daily; prophylaxis is once daily 1, 5
- Do not skip renal adjustment: Failure to reduce dose when creatinine clearance is <60 mL/min leads to drug accumulation and potential toxicity 1, 9
- Do not stop early: Complete the full 5-day course even if symptoms resolve, as early discontinuation increases resistance risk 1, 5
- Age alone does not require dose reduction: Elderly patients (≥65 years) receive standard adult dosing unless renal function is impaired 1, 5
Clinical Efficacy
- Oseltamivir reduces illness duration by approximately 1–1.5 days when initiated within 48 hours of symptom onset 5, 8
- The drug decreases the incidence of secondary complications (bronchitis, pneumonia, sinusitis) and reduces subsequent antibiotic use 3, 8
- Protective efficacy for prophylaxis is 74–87% when used during periods of influenza activity 6